EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Expert Q&A

13. How do we change pharmacy partners without turning an operational migration into an unsafe treatment switch?

Dose Diligence research deskSection 06 · Page 16 of 22Last updated 17 Nov 2026

Framing: separate a pharmacy transfer from a change in medicine, formulation, concentration or device. LillyDirect states that medicine or formulation changes require a new valid prescription and that dose changes come from the prescriber. FDA’s compounded-semaglutide alert documents the risks of concentration and measurement confusion. (lilly.com)

Put to: Robert Kushner and Michael Ganio.
Buyer owner: Medical director, with the COO managing execution.

Why it matters: Procurement should organise continuity while leaving patient-specific treatment decisions with clinicians.

A good answer should cover:

  • Identifying patients awaiting supply, holding existing supply or requiring clinical review.
  • Confirming whether a transfer, new prescription, new counselling or different instructions are needed.
  • Reconciling outstanding orders, payments and shipments to prevent duplicates.
  • Clinician-led management of interruptions, product changes and restart questions.
  • Patient communications that distinguish the dispensing change from any clinical change.

Follow-up that tests the answer: “Which patients should not enter a bulk migration workflow, and what information must the reviewing clinician have?”

Evidence to request: A clinician-approved migration protocol, exception queue and patient communication pack. Require a controlled pilot and reconciliation before broad rollout; do not create an automatic cross-product dose-conversion table as a procurement shortcut.

Expert quote — reserved: ________________________________________

Sources cited on this page

  1. lilly.com · Source 1 ↗https://www.lilly.com/lillydirect/faq
Section sources →